Nutex Health Q1 2024 revenue $67.5M (+20% YoY); net loss narrows to $0.4M

Nutex Health Inc.

2024-Q1 EPS reported -$0.01 revenue$67,453,787

Revenue $67.5M vs $56.3M YoY; hospital visits up 21.1% to 40,068.
Hospital division operating income rose 119% to $10.5M; overall operating income $1.5M vs loss of $4.5M.
Adjusted EBITDA $4.6M (+92% YoY); net cash from operations $3.1M.
Balance sheet: cash $30.0M, long-term debt $26.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nutex Health Inc. reported first quarter 2024 results: revenue $67.5 million, net income Net loss attributable to Nutex Health Inc. of $0.4 million.

Period: first quarter 2024
Revenue: $67.5 million
Net income: Net loss attributable to Nutex Health Inc. of $0.4 million
Result: reported results

Exact text from the filing

Total revenue of $67.5 million as compared to total revenue of $56.3 million for the three months ended March 31, 2023, an increase of approximately 20%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 6.7% in 2024 compared to 2023. ● Total visits from the Hospital Division were 40,068 for the first quarter 2024 as compared to 33,085 for the first quarter 2023, an increase of 6,983 or 21.1%. Of this visit growth, mature hospitals increased by 5.3% in 2024 compared to 2023. ● Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $5.1 million for the three months ended March 31, 2023.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Nutex Health Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.